(S) - 6-chloro-3,4-dihydro-2h-thieno [3,2-e] - 1,2-thiazine-4-alcohol 1,1-dioxide

‌Ozenoxacin Intermediate D (CAS 446299-81-6) | High-Purity Building Block for Antibacterial API Synthesis‌
‌Google Search Keywords‌: Ozenoxacin Intermediate D, CAS 446299-81-6, Ozenoxacin Synthesis Material, Antibacterial Intermediate, Quinolone API Precursor

🔬 ‌Product Overview‌
Ozenoxacin Intermediate D (CAS 446299-81-6) is a specialized chemical compound essential for the synthesis of ‌Ozenoxacin‌, a potent non-fluorinated quinolone antibiotic used to treat bacterial skin infections. This intermediate plays a critical role in achieving high-purity Ozenoxacin API, ensuring compliance with pharmaceutical manufacturing standards.
‌Primary Function‌: Enables precise and scalable production of Ozenoxacin API.
‌Applications‌: Antibacterial drug development, topical formulations, veterinary therapeutics.

✅ ‌Key Advantages‌
⭐ ‌Superior Purity‌

• Purity ≥99% (HPLC/LC-MS validated), minimizing side reactions and ensuring batch-to-batch consistency.

⚙️ ‌Optimized Synthesis‌

• Reduces synthesis steps by 15-20%, enhancing production efficiency and cost-effectiveness.

🌡️ ‌Robust Stability‌

• Long-term stability at 2-8°C, ideal for global shipping and extended storage.

📜 ‌Regulatory Compliance‌

• Manufactured under ‌ICH Q7‌ and ‌GMP‌ guidelines, aligned with USP/EP requirements.

📋 ‌Applications‌

1. ‌API Manufacturing‌: Key precursor in Ozenoxacin API production for topical antibacterial creams.

2. ‌Veterinary Antibiotics‌: Supports development of antibacterial solutions for animal health.

3. ‌Generic Drug Formulations‌: Critical for cost-effective alternatives to branded quinolone therapies.

4. ‌R&D Innovation‌: Used in studies to modify quinolone structures for enhanced efficacy.

🏅 ‌Quality Certifications‌

• Rigorously tested via ‌HPLC, GC, NMR, and Mass Spectrometry‌ (USP/EP/ICH compliant).

• Comprehensive Certificate of Analysis (CoA) with impurity profiling and spectral data.

🌐 ‌Market Trends‌
The global quinolone antibiotic market is projected to grow at ‌5.5% CAGR (2024-2030)‌, driven by rising skin infection rates and demand for non-fluorinated alternatives. Ozenoxacin intermediates are pivotal in meeting production needs for topical antibacterial drugs, particularly in emerging markets.

🔍 ‌Why Choose Us?‌

• ‌Bulk Customization‌: Flexible batch sizes (grams to metric tons) with tailored purity grades.

• ‌Fast Delivery‌: Global logistics with temperature-controlled packaging for sensitive intermediates.

• ‌Technical Expertise‌: End-to-end support for API synthesis, quality control, and regulatory submissions.